Susquehanna International Group
CTIC

Susquehanna International Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Susquehanna International Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-205,500
Closed -$863K – 13782
2023
Q1 		$863K Buy
205,500
+86,900
+73% +$451K ﹤0.01% 7206
2022
Q4 		$713K Sell
118,600
-327,200
-73% -$1.79M ﹤0.01% 6977
2022
Q3 		$2.6M Buy
445,800
+139,200
+45% +$867K ﹤0.01% 4380
2022
Q2 		$1.83M Buy
306,600
+46,900
+18% +$240K ﹤0.01% 5100
2022
Q1 		$1.21M Buy
259,700
+118,800
+84% +$354K ﹤0.01% 6635
2021
Q4 		$349K Buy
140,900
+128,100
+1,001% +$313K ﹤0.01% 10121
2021
Q3 		$38K Sell
12,800
-215,600
-94% -$587K ﹤0.01% 12438
2021
Q2 		$571K Buy
228,400
+122,700
+116% +$294K ﹤0.01% 9291
2021
Q1 		$308K Sell
105,700
-44,000
-29% -$144K ﹤0.01% 10544
2020
Q4 		$482K Sell
149,700
-51,700
-26% -$172K ﹤0.01% 8374
2020
Q3 		$433K Buy
201,400
+184,300
+1,078% +$235K ﹤0.01% 7967
2020
Q2 		$20K Buy
17,100
+3,000
+21% +$3.17K ﹤0.01% 9923
2020
Q1 		$13K Sell
14,100
-60,900
-81% -$69.8K ﹤0.01% 10015
2019
Q4 		$119K Buy
75,000
+37,300
+99% +$35.3K ﹤0.01% 9063
2019
Q3 		$31K Sell
37,700
-110,200
-75% -$84.1K ﹤0.01% 9892
2019
Q2 		$127K Buy
147,900
+111,200
+303% +$103K ﹤0.01% 9492
2019
Q1 		$36K Buy
36,700
+23,900
+187% +$25.2K ﹤0.01% 8531
2018
Q4 		$9K Sell
12,800
-3,300
-20% -$5.42K ﹤0.01% 8758
2018
Q3 		$35K Sell
16,100
-51,200
-76% -$127K ﹤0.01% 8919
2018
Q2 		$335K Sell
67,300
-13,500
-17% -$59.1K ﹤0.01% 7628
2018
Q1 		$315K Buy
80,800
+53,100
+192% +$187K ﹤0.01% 7559
2017
Q4 		$74K Sell
27,700
-25,400
-48% -$74.4K ﹤0.01% 8809
2017
Q3 		$169K Sell
53,100
-29,500
-36% -$98.5K ﹤0.01% 8127
2017
Q2 		$273K Buy
82,600
+12,000
+17% +$46.7K ﹤0.01% 7746
2017
Q1 		$297K Buy
70,600
+66,680
+1,701% +$308K ﹤0.01% 7355
2016
Q4 		$16K Buy
+3,920
New +$16.3K ﹤0.01% 9450
2016
Q3 		– Sell
-4,190
Closed -$14K – 9657
2016
Q2 		$14K Sell
4,190
-4,540
-52% -$20.8K ﹤0.01% 8411
2016
Q1 		$46K Sell
8,730
-35,070
-80% -$280K ﹤0.01% 8682
2015
Q4 		$539K Buy
43,800
+9,750
+29% +$130K ﹤0.01% 6622
2015
Q3 		$497K Buy
34,050
+1,870
+6% +$32.3K ﹤0.01% 7137
2015
Q2 		$628K Sell
32,180
-32,620
-50% -$630K ﹤0.01% 7178
2015
Q1 		$1.17M Buy
64,800
+24,270
+60% +$546K ﹤0.01% 5425
2014
Q4 		$957K Buy
40,530
+1,890
+5% +$43.7K ﹤0.01% 5959
2014
Q3 		$935K Sell
38,640
-10,060
-21% -$262K ﹤0.01% 6053
2014
Q2 		$1.37M Buy
48,700
+10,520
+28% +$316K ﹤0.01% 5409
2014
Q1 		$1.3M Buy
38,180
+27,350
+253% +$935K ﹤0.01% 5060
2013
Q4 		$208K Buy
+10,830
New +$197K ﹤0.01% 8209

Other funds holding CTIC

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Susquehanna International Group's CTIC Position: Q2 2023 in Review

Susquehanna International Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 813,905 shares — an estimated $3.42M sold.

Susquehanna International Group first reported a position in CTIC in Q2 2013 and held it in 26 quarters. The position peaked at $3.75M in Q3 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

  • Susquehanna International Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
  • Susquehanna International Group sold 813,905 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $3.42M.
  • Susquehanna International Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 26 quarters.
  • Susquehanna International Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $3.75M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.